Alleged isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System
- 30 September 2013
- journal article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 69 (3), 393-398
- https://doi.org/10.1016/j.jaad.2013.04.031
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The Metoclopramide Black Box Warning for Tardive Dyskinesia: Effect on Clinical Practice, Adverse Event Reporting, and Prescription Drug LawsuitsThe American Journal of Gastroenterology, 2013
- Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort StudyJournal of Investigative Dermatology, 2013
- Isotretinoin and Risk for Inflammatory Bowel DiseaseJAMA Dermatology, 2013
- Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Case–Control StudyThe American Journal of Gastroenterology, 2010
- Isotretinoin Is Not Associated With Inflammatory Bowel Disease: A Population-Based Case–Control StudyThe American Journal of Gastroenterology, 2009
- Psoriasis associated with ulcerative colitis and Crohn's diseaseJournal of the European Academy of Dermatology and Venereology, 2009
- Possible Association Between Isotretinoin and Inflammatory Bowel DiseaseThe American Journal of Gastroenterology, 2006
- Vaccine Adverse Event Reporting System Reporting Source: A Possible Source of Bias in Longitudinal StudiesPEDIATRICS, 2006
- Long-term safety of isotretinoin as a treatment for acne vulgarisBritish Journal of Dermatology, 1994
- Isotretinoin for acne vulgaris-10 years later; a safe and successful treatmentBritish Journal of Dermatology, 1993